Related Experiment Videos
[Heart failure and sudden death]
Tadakazu Hirai1, Hidetsugu Asanoi
1Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 9, 2005
Summary
Sudden death in heart failure (HF) patients is complex. While medications and implantable cardioverter defibrillators (ICDs) improve survival, individualized care for left ventricular systolic dysfunction is crucial.
Area of Science:
- Cardiology
- Heart Failure Research
- Sudden Cardiac Death
Context:
- Sudden death in heart failure (HF) patients presents significant clinical challenges.
- Neurohumoral activation is implicated in triggering lethal ventricular arrhythmias.
- Current treatments include pharmacotherapy and device-based interventions.
Purpose:
- To review the complexity of sudden death in heart failure.
- To discuss the role of neurohumoral activation in arrhythmias.
- To evaluate the efficacy and cost-effectiveness of implantable cardioverter defibrillators (ICDs) in patients with left ventricular (LV) systolic dysfunction.
Summary:
- Pharmacological agents like ACE inhibitors, ARBs, and beta-blockers improve survival in HF.
- Prophylactic ICD therapy reduces mortality in LV systolic dysfunction but may not be suitable for all patients.
- Individualized patient care is essential for managing LV systolic dysfunction and preventing sudden death.
Impact:
- Highlights the need for personalized treatment strategies in heart failure management.
- Emphasizes careful consideration of prophylactic ICD therapy's benefits versus costs.
- Contributes to understanding the multifactorial nature of sudden cardiac death in HF patients.